We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

By LabMedica International staff writers
Posted on 22 Mar 2023
Print article
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the existing diagnostic tests for T2D based on fasting plasma glucose (FPG), oral glucose tolerance test (OGTT) and glycosylated hemoglobin A1c (HbA1c) rely on invasive blood detection. Now, a research team working on a new non-invasive screening method for T2D has used self-developed proton transfer reaction-mass spectrometry (PTR-MS) to detect volatile organic compounds (VOCs) in T2D patients' urine samples.

The research by investigators from the Institute of Health and Medical Technology, Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS, Anhui, China) was based on sniffing urinary acetone by PTR-MS. Acetone in urine is one of the ketones produced by fat metabolism. As T2D patients experience insufficient glucose utilization and storage in their blood, their bodies accelerate the metabolism of urinary acetone. In the multicenter study involving 180 T2D patients and 180 healthy individuals, a diagnostic model with an accuracy of 81.3% (sensitivity: 73.3%, specificity: 89.3%) was established by using urinary acetone at center 1, and a threshold of 690.1 ppbv was obtained. The model was subsequently validated in the other two participating centers, yielding similar results. Moreover, the diagnostic accuracy of this approach was found to be on par with the diagnostic method used in the clinic.

"Sniffing T2D through urinary acetone is safe, non-invasive, fast, and accurate," said XU Wei, first author of the paper. "We hope that the method can provide reference for screening and diagnosis of T2D."

Related Links:
Hefei Institutes of Physical Science, CAS

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.